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ABSTRACT
The utilization of cardiac progenitor cells (CPC) has been shown to
induce favorable regenerative effects. While there are various populations of
endogenous CPCs in the heart, there is no consensus regarding which
population is the most ideal for cell-based regenerative therapy. Identifying an
Islet-1+ (Isl-1+) early-stage progenitor population with enhanced stemness,
multipotency and differentiation potential would be beneficial for regenerative
therapy. Spalt-like transcription factor 4 (SALL4) plays a role in embryonic
development as well as proliferation and expansion of hematopoietic progenitor
cells. We hypothesize that SALL4 will be co-expressed in Isl-1+ cardiac
progenitor cell clones isolated from human cardiac tissue and represent a premesendodermal progenitor population. Ingenuity Pathway Analysis revealed Isl1+ human neonates exhibit enhanced stemness properties compared to Isl-1+
adult CPCs. We compared RNA-seq based transcriptomic data from human
neonatal Isl-1+ CPC clones with that of published time-course specific RNASeq based transcriptomic data collected from various stages of cardiac
differentiation from human pluripotent stem cells (hPSCs). This approach
elucidated genes that are highly expressed at different stages of cardiac
development giving insight into the developmental state of SALL4 expressing
Isl-1+ neonatal CPCs. In addition to SALL4, evidence suggests that SOX2,
EpCAM and TBX5 are expressed early along the cardiovascular pathway.
CPCs were previously derived from human cardiac tissue discarded at surgery,
clonally expanded, and screened for expression of Isl-1. RNA was isolated from
iii

individual human neonatal (n=10) Isl-1+ CPCs, cDNA was synthesized, and
real time PCR was done. We utilized RT-PCR to identify the expression of
SALL4, SOX2, EpCAM and TBX5 in individual neonatal Isl-1+ CPC clones. Gel
electrophoresis of the PCR products was used to confirm that transcripts of the
correct size were amplified. Results demonstrate that 9 out of 10 Isl-1+ neonatal
CPC clones tested expressed SALL4. To further substage neonatal Isl-1+ CPC
clones that expressed SALL4, SOX2, EpCAM and TBX5, clones were tested for
expression of TFAP2C. These features will allow for the identification and
isolation of an optimal early-stage CPC clone that may be of value in
regenerative therapeutic applications.
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CHAPTER ONE
INTRODUCTION

Cardiovascular disease (CVD) refers to a number of disorders of the heart
and blood vessels. According to the World Health Organization, cardiovascular
diseases are the number one cause of death globally. It is estimated that by
2030, nearly 23.6 million people will die of CVD per year (Mozaffarian et al.,
2015). Prevalence of CVD in adults over the age of 20 is 49.2% and increases
with age in both males and females (Virani et al., 2021). Interestingly, 1 out of
every 4 deaths in the United States is a result of CVD with a death occurring
every 37 seconds (Virani et al., 2021). With more than 100,000 people on the
national heart transplant list, there is a need to address alternative options for
cardiac repair. Current options for repair range from simple lifestyle changes to
coronary artery bypass grafting, heart valve repair or replacement, insertion of a
pacemaker, and more. Surgical repair of the heart is often successful but comes
with risks such as, bleeding, infection, stroke, even death (Asahq). There is an
unmet need to drive regenerative solutions into clinical trials. Current therapies
for CVD are unable to replace dead cardiomyocytes. Cardiomyocytes are the
main cardiac cell type lost in cardiovascular disorders, including heart failure,
myocardial infarction, and ischemia, and replacing these cells could potentially
restore heart function (Le et al., 2016). According to clinicaltrials.gov, there are
90 studies that use autologous stem cells as an intervention for heart repair
(clinicaltrial.gov). Most interventions lack functional efficacy for cardiovascular
1

repair, and many do not reach completion. Consequently, there is a need to
identify a cardiovascular progenitor cell (CPC) that can differentiate into a variety
of cardiac subtypes and will demonstrate the ability to improve function.
Early heart development involves several types of progenitor cells that are
derived from the mesoderm, proepicardium, and neural crest (Tan et al., 2020).
Ultimately, this leads to the formation of the four chambered heart by gestational
week seven via heart looping and complex cellular interactions (Tan et al., 2020).
Heart development involves two distinct cardiac progenitor cell pools termed the
first heart field (FHF) and second heart field (SHF) progenitor cells that are
derived from the lateral plate mesoderm and neural crest cells. Overlap in
expression of the FHF and SHF markers have led to debate as to where these
two pools originate. It has been proposed that the FHF and SHF arise from a
common progenitor that segregates into the heart fields early in development
(Meilhac et al., 2004). Understanding the origin of CPCs may elucidate the
markers that are expressed at various stages of CPC development and allow the
identification of an early-stage progenitor with multi-lineage potential.
Fate mapping and lineage tracing experiments can track cell lineages and
their progeny, aiding in the identification of an early-stage progenitor population.
These experiments cannot be done in humans; therefore, the mouse is the most
common model. Fate mapping studies have postulated that an early CPC exists
at the primitive streak stage of CPC development and may have the ability to
give rise to multiple cells of the heart (Peterson et al., 2021). According to the Jia
group cell fate mapping experiments demonstrated that cardiac progenitor cells
2

in mice form from MESP1-expressing cells that leave the primitive streak during
gastrulation on mouse development day E6.5 (Jia et al., 2018). Furthermore, fate
mapping studies in mice have shown that cardiac mesoderm progenitors are the
first to ingress through the primitive streak during gastrulation, later contributing
to the FHF and subsequently the SHF (Meilhac et al., 2004). Specific markers
such as Brachyury (T), Eomes, and MESP1 are some of the earliest markers to
date that are present before or during ingression through the primitive streak and
formation of the heart fields as evidenced in mouse lineage studies. Following
the primitive streak stage, at E7.5, cells express NKX2-5 and the transcription
factor Islet-1 (Isl-1+) and demonstrate multi-lineage potential generating
cardiomyocytes, vascular smooth muscle cells, and endothelial cells (Jia et al.,
2018). According to Cai et al., Isl-1+ identifies a distinct population of
undifferentiated progenitors evidenced through fate mapping and in situ
hybridization (Cai et al., 2003). In our lab, we isolate CPCs from discarded
human cardiac tissue on the basis of Isl-1+ expression.
Isl-1+ is well-recognized as a marker that identifies early cardiac stem
cells. However, according to Fuentes et al. Isl-1+ expressing cells are most
abundant in neonatal tissue (Fuentes et al., 2013). Isl- 1+ is a transcription factor
of the LIM-homeodomain family. Isl-1+ CPCs generate cells of the three cardiac
lineages in vitro and in vivo: cardiomyocytes, vascular smooth muscle, and
endothelial cells (Fuentes et al., 2014; Gao et al., 2019). The transcription factor
Isl-1+ is required early in development for the survival, proliferation, and
migration of cardiac progenitors into the primordial heart. In one study, Isl-1+
3

deficient mice lacked the outflow tract, right ventricle, and most of the atria
(Weinberger et al., 2012). Fate-mapping has identified Isl-1+ cells in the atria,
ventricles, and epicardium of the heart. Isl-1+ knockout mice exhibited growth
retardation on day 9.5 in development and died on day 10.5 (Weinberger et al.,
2012). Isl-1+ is transiently expressed in the second heart field (SHF) progenitor
cells before their differentiation and integration into the heart tube (Weinberger et
al., 2012; Barreto et al., 2019). Isl-1+ functions during heart development by
shaping chromatin and creating a gene regulatory network (GRN) that drives
cardiac development and defines cardiomyocyte identity (Gao et al., 2019).
Specifically, Isl-1+ binds to and regulates the expression of transcription factors,
epigenetic modifiers, and closed chromatin working with a complex (Brg1Baf60c) to induce alterations in the chromatin landscape that enables the
activation of genes that define cardiomyocytes (Gao et al., 2019). Gao et al.,
found that Isl-1+ target genes such as WNT5, JAG1, SMAD6, TBX3, TBX5, and
TBX20 play a role in development of the atrioventricular canal and outflow tract
morphogenesis. Isl-1+ expression is predominantly but not exclusively found in
SHF progenitors (Ma et al., 2008).
Isl-1+ cardiac progenitor cells have also been studied for their use in
cardiac repair (Ren et al., 2021). Multipotent Isl-1+ progenitors appear early in
mesodermal differentiation due to co-expression of pluripotency genes but
provide evidence of ventricular progenitor activity in vivo as shown by grafting
studies (Foo et al., 2018). Foo et al., generated human ventricular progenitors
isolated on the basis of Isl-1+ that were able to form a large ventricular muscle
4

patch on a murine kidney (Foo et al., 2018). Additionally, the patch was able to
engraft into uninjured and injured murine hearts. Bartulos et al., isolated Isl-1+
CPCs from a murine embryonic stem cell (ESC) line and generated
cardiospheroids (Bartulos et al., 2016). The Isl-1+ cardiospheroids showed
enhanced differentiation capacity and effectively engrafted in the infarcted heart
4 weeks after injection, reducing scar size and increasing blood vessel formation.
Another study transplanted Isl-1+ CPC patches that were generated using small
intestinal submucosa extracellular matrix (SIS-ECM) which was then placed in
mice following a myocardial infarction (MI) (Wang et al., 2017). The Isl-1+ CPCs
were derived from mouse ESCs and were shown to differentiate in the SIS-ECM
which served as a biodegradable scaffold. The SIS-ECM patches seeded with
Isl-1+ CPCs and transplanted into the MI heart in vivo showed an increase in left
ventricular ejection fraction (LVEF) from 33.49 to 62.16 (Wang et al., 2017).
LVEF is defined as the amount of blood the left ventricle pumps out with each
contraction. The LVEF in the heart is normally within the range of 55% to 70%.
A LVEF less than 35% is considered severe heart failure in which the right and
left ventricle do not pump in unison (Cleveland Clinic). These studies have led to
clinical advances in heart regenerative therapy.
The ESCORT trial led by Menasche et al., is the first clinical trial using Isl1+ CPCs. Menasche et al., developed a population of hESC-derived CPC
expressing Isl-1+ and Stage-Specific Embryonic Antigen (SSEA-1) (Menasche et
al., 2015). SSEA-1 is a surface marker that labels cells in a differentiation
pathway and induces Isl-1+ expression. In this study, SSEA-1 was used to
5

identify a pure population of Isl-1+ CPCs with high levels of SSEA-1. Impure cell
populations can cause undesirable effects such as variable engraftment, tumor
formation and spontaneous differentiation (Fuerstenau-Sharp et al., 2015). Purity
of a sample is especially important when isolating a cell population that is
differentiating and intended for cell-based repair. A small fraction of
undifferentiated cells can cause teratoma formation. In the Menasche study, the
early-stage cells were embedded into a fibrin scaffold in patients suffering from
ischemic left ventricular dysfunction. After cell treatment, all patients
symptomatically improved with an increase in LVEF at 3 months post-delivery.
Specifically, LVEF increased from 26% to 36% with no arrythmias, tumor
formation, or immunosuppression related events. While this trial shows promise
in cardiac regenerative therapy, safety is still a major concern. Patients in the
ESCORT trial developed alloimmunization and one patient died of heart failure
after 22 months. According to Menasche et al., allowing the early-stage
progenitor cells to differentiate in vitro would unravel their ability to actively
contract. However, identifying an optimal cell whose phenotype closely matches
that of the recipient tissue would be the most ideal candidate. The ESCORT trial
shows that hESCs , if purified and isolated at any early stage of development,
have potential benefits for cardiac regenerative therapy.
Pluripotent stem cells (PSCs) is a collective term for Embryonic Stem
Cells (ESCs) and Induced Pluripotent Stem Cells (iPSCs). While using PSCs for
clinical trials has shown promise, utilization of these cells remains arguable. The
use of PSCs is invaluable for tracing the events of early-stage cardiovascular
6

differentiation using cells derived from humans. ESCs may be used for stem cellbased applications but their use has potential risk of immune rejection after
transplantation, teratoma formation from residual pluripotent stem cells, graft
associated arrythmias and ethical concerns (Pawani & Bhartiya, 2013).
Additionally, hESC derived cells for heart repair often do not match their in vivo
counterparts displaying differences in electrophysiological parameters,
contraction, and gene expression profiles (Churko et al., 2018). In contrast to
ESCs, iPSCs overcome some of the limitations of ESCs. For instance, iPSCs are
derived from somatic cells which can be patient-specific and can be
reprogrammed to a pluripotent state. While the application of PSCs for cell based
regenerative therapy poses potential risks, murine and human PSCs have been
valuable in studies designed to investigate cardiac development in vivo.
Pluripotent stem cells have the ability to self-organize into 3D structures
called organoids resembling embryo-like tissue patterns in vitro (Drakhlis et al.,
2021). For example, murine PSC-derived pre-cardiac organoids have been
shown to generate two heart fields (FHF and SHF) that were highly similar to
their in vivo counterparts, providing a model for studying the morphological
aspects of heart development (Andersen et al., 2018). PSCs can also be
differentiated down a specific lineage to study stages of development.
Specifically, human PSCs have been differentiated into cardiac mesoderm cells
(CMCs) expressing early and late cardiac transcription factors (Vahdat et al.,
2019). Additionally, murine, and human PSCs have been differentiated down the
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mesendoderm lineage to study genes that are highly expressed at this stage of
CPC development.
Mesendoderm is a transient stage in CPC development that differentiates
toward the mesoderm and definitive endoderm lineage (Figure 1). Carpenedo et
al., differentiated hPSCs toward the mesendoderm lineage to identify which
genes are most highly expressed at the mesendoderm stage of cardiac
differentiation (Carpenedo et al., 2019). RNA was collected from each stage of
differentiation for RNA-Seq application to identify the expression of genes at
each stage. Because the mesendoderm stage is transient, the Tian group
identified transcription factor WHSC1 in murine PSCs and found that it is
required for efficient pluripotency exit and mesendoderm specification. A small
hairpin lentiviral construct was used to knockdown WHSC1 expression revealing
elevated expression levels of pluripotency genes such as, REX1, OCT4
(POU5F1), Nanog and Lin28a (Tian et al., 2019). Additionally, WHSC1 depleted
ESCs showed a strongly reduced expression of mesendoderm markers such as
Gata4, T, SOX17 and KDR. Differentiation events identified using hPSCs are
typically marked by the downregulation of pluripotency markers such as OCT-4,
SOX2 and Nanog in conjunction with the activation of lineage-specific gene
expression (Muhr & Ackerman, 2021). Signaling pathways such as canonical
WNT, FGF, and BMP initiate the activation of transcription factors that regulate
genes associated with a cardiac phenotype such as, NKX2 – 5, Gata 4, TBX5
(Witman et al., 2020). These early stages of differentiation are not clearly defined
but are currently being studied using transcriptomics in an effort to characterize
8

early-stage cardiovascular progenitors as they differentiate along the
mesodermal lineage. Mesendoderm stage cells have been used for cell-based
repair with promising results and represent a population of interest for
investigators in the field of cardiovascular stem cell research (Boumelhem et al.,
2017).

Figure 1: Representation of in vitro CPC differentiation from a pluripotent (hPSC)
cell state. Cell stages: hPSC, pre-mesendoderm (Pre-MES), mesendoderm
(MES), definitive endoderm (DE), mesoderm (ME), pre-cardiac mesoderm, first
heart field (FHF) and second heart field (SHF).
Transcriptomics is an innovative technology that enables researchers to
understand the heterogeneity and regulation of diverse cell phenotypes (Xiong et
al., 2020). The transcriptome is the entire assembly of RNA transcripts in a given
cell type. RNA-Seq transcriptomic analysis is a recently developed technology
that uses high-throughput sequencing approaches to determine the sequence of
all RNA transcripts in a given specimen (Reuther et al., 2019). Transcriptomics is
a valuable approach that can be used to identify early-stage cardiac progenitor
cells which would lower the risk of immune rejection, effectively engraft into the
injection site, and have the ability to differentiate in vivo into all cells of the
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cardiovascular lineage. The use of RNA-Seq transcriptomics on hPSCs
committed to a cardiac fate elucidates transcripts that are present at specific
stages of cardiac development. For example, Churko et al., performed a time
course RNA-Seq analysis and used single cell populations of iPSCs that were
differentiated along the cardiovascular lineage up to day 90. They collected RNA
for RNA-Seq at various time points which corresponded to a defined stage of
cardiac differentiation. This data helps researchers to understand the transcripts
that are expressed at different stages of cardiomyocyte development. Similarly,
Den Hartogh et al., differentiated hESCs using WNT pathway inhibitor Xav939
and collected RNA at specific time points to study the temporal expression of key
molecules involved in cardiac lineage commitment upon differentiation (Den
Hartogh et al., 2016). Time points were similar to those defined by Churko et al.
These studies allow for the identification of early-stage cardiac progenitors by
highlighting transcripts that are expressed early in CPC development (Table 1).
SALL4 is one example of a stem cell gene required for ESC pluripotency
and early embryonic development (Xiong, 2014). Koshiba-Takeuchi et al., found
that SALL4 and TBX5 ensure precise patterning of embryonic limb and heart
(Koshiba-Takeuchi et al., 2006) while Pantier et al., reported that loss of
pluripotency is triggered by downregulation of SALL4 (Pantier et al., 2021).
SALL4 plays a role in embryonic stem cell self-renewal (Tatetsu et al., 2016). By
binding to the regulatory region of genes such as OCT4 and SOX2, SALL4
regulates the pluripotency transcriptional network and controls the stemness
gene EpCAM to maintain pluripotency (Tatetsu et al., 2016). SALL4 is
10

predominantly an enhancer binding protein. According to Miller et al., SALL4
occupancy of enhancer sequences along with pluripotency-associated
transcription factors can enhance or interfere with transcription depending upon
the target gene (Miller et al., 2016). It has been reported that SALL4 is capable of
enhancing bone marrow regeneration and dramatically accelerates the
expansion of hematopoietic stem cells from peripheral blood (Xiong et al., 2020).
Tahara et al., found that SALL4 is essential for maintenance of
neuromesodermal progenitors and promotes mesoderm commitment while
inhibiting neural commitment (Tahara et al., 2019). The key role of SALL4 in
self-renewal and stemness, suggests that this transcription factor may be
expressed in early-stage cardiovascular progenitors isolated from neonates.
The search for the “ideal” cell type for heart repair has been an ongoing
quest (Menasche, 2020). Cardiac progenitor cells appear early in embryonic
development as demonstrated by genetic lineage tracing. While there are a
number of cardiac progenitor populations for cell-based heart repair, research
shows application of such cells to have limited efficacy. Isl-1+ marks an earlystage CPC and has been used to isolate clonal populations of early-stage
cardiovascular progenitor cells in our laboratory. Specifically, neonatal Isl-1+
cardiovascular progenitor cells have been the focus of research in our laboratory
due to their enhanced regenerative ability. Additionally, select mesendodermal
and pre-cardiac markers have previously been characterized in our lab.
According to Belair et al., SALL4 is necessary for mesendoderm specification
and differentiation (Belair et al., 2020).
11

The aim of my project is to determine whether or not SALL4 may be used
as a tool to isolate and identify the earliest stage CPC from human patients.
These early-stage cells may then be of value for use in regenerative therapy.
Results from this project will elucidate markers expressed at various
developmental stages of CPC isolated from neonatal patient samples. The
objective is to subsequently identify an early-stage CPC with a great degree of
multipotentiality and cardiac repair potential.

12

Developmental Stage (in
vitro)
Pluripotent

Mesendoderm

FHF

SHF

Epicardial

Markers
SALL4
SOX2
EPCAM
TBX3
POU5F1
MESP1
T
EOMES
GSC
SOX17
GATA4
MIXL1
HCN4
NKX2-5
TBX5
HAND1
ISL1
MEF2C
FGF10
TBX18
WT1

Human
iPSCs
D3
D0-D1
D1
D2-D9
D0
D3
D1-D3
D2
D1-D2
D3
D1-D90
D2
D9-D14
D7
D4-D90
D3-D90
D6
D6
D6
X
D30

Human
ESCs
D0-D10
D0-D5
D0
X
D0
D3
X
D3
D3
D3,D7
D3-D14
D3
X
D7-D14
X
X
D7-D10
D7-D10
X
D7-D14
D7-D14

Table 1: Genes which are highly expressed at different stages of CPC
development. Genes are identified from published RNA-Seq based
transcriptomic analyses based on in vitro differentiation of hiPSCS (Churko et al.,
2018) and hESCs (Den Hartogh et al., 2016) toward a cardiomyocyte fate.
(X=not represented in transcriptomic data)
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CHAPTER TWO
METHODS

Ethics Statement and Maintenance of Cardiac Progenitor Cells
Human cardiac progenitor cell clones were previously isolated and were
available for use in this project. The Institutional Review Board of Loma Linda
University approved the protocol for use of tissue that was discarded during
cardiovascular surgery, without identifiable private information, for this study with
a waiver of informed consent.
Cardiac Progenitor Cell Expansion
CPC clones were isolated from cardiac tissue of five neonatal (1 day-1
month) and five adults (57-72 years) patients undergoing cardiovascular surgery
(Fuentes et al., 2013). Twenty previously isolated clones were expanded for use
in the experiments described here. Briefly, atrial tissue was cut into small clumps
(~1.0 mm3) then enzymatically digested using collagenase at a working
concentration of 1.0mg/mL for 2 hours at 37 degrees Celsius. The resulting
solution was then passed through a 40-um cell strainer. Cells were cloned in a 96
well plate by limiting dilution to a final concentration of 0.8 cells per well to create
populations for expansion. Clones were screened for the expression of Isl-1+ and
supplemented with growth media comprised of 10% fetal bovine serum (Thermo
Scientific, Waltham, MA), 100 µg/mL Penicillin-Streptomycin (Life Technologies,
Carlsbad, CA), 1.0% minimum essential medium non-essential amino acids
14

solution (Cat no. 11120052, Life Technologies, Carlsbad, CA), and 22%
endothelial cell growth media (Lonza, Basel, Switzerland) in Medium 199 (Life
Technologies, Carlsbad, CA) (Fuentes et al., 2013).
RNA Sequencing
RNA samples isolated from neonatal and adult Isl-1+ CPC clones were
previously sent to PrimBio Research Institute for RNA-Sequencing (Exton, PA,
USA). rRNA was removed from the total RNA sample using an rRNA removal kit
from Illumina (San Diego, CA, USA) (cat# MRZG12324). Sequencing libraries
were assembled with an Ion Total RNA-Seq Kit v2 from Thermo Fisher
(Waltham, MA, USA) (Cat# 4479789). Nucleic acid binding beads from Ambion
(Austin, TX, USA) were used to purify the cDNA library (Cat# 4479681) prior to
PCR amplification. Agilent dsDNA High Sensitivity kit was used to determine the
quality of the library (Agilent, Santa Clara, CA, USA). The samples were enriched
via an Ion OneTouch ES instrument and an Ion PI™ Hi-Q™ OT2 200 Kit
(Thermo Fisher, Waltham, MA, USA). Sequencing was performed using an Ion
Proton sequencer (Thermo Fisher, Waltham, MA, USA) and a species-specific
protocol for our samples. Next, sequence files were aligned to the human
genome and quality was determined using the Strand NGS program.
Normalization and quantification of the aligned reads were performed using the
Deseq algorithm within the Strand NGS program. The Audic–Claverie test and
the Benjamini–Hochberg correction test were used for statistical analysis.
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Significance was determined using a 2.0-fold change minimum cutoff. (Camberos
et al., 2021)
Transcriptomic Analysis

To analyze transcriptomic data, Isl-1+ neonatal (N=3) and adult (N=3)
pooled CPC gene transcripts were uploaded to Ingenuity Pathway Analysis
(IPA) (Qiagen, Valencia, CA, USA). Core analysis was performed with specific
parameters set for human cells (Camberos et al., 2021). Categories specific to
cancer and viral disease were removed and categories with a p-value < 0.05
were reported. IPA’s upstream regulator analysis tool was used to visualize
significant networks generated from uploaded transcriptomic data. Lastly,
transcripts were uploaded to StemChecker (http://stemchecker.sysbiolab.eu/as)
to determine the expression profile of the neonatal Isl-1+ CPC pool versus the
adult Isl-1+ CPC pool. StemChecker refines the uploaded gene lists by
identifying overlap with published literature in which stem cell gene sets
(stemness signatures) are reported (Pinto et al., 2015). Stemness signatures are
further categorized into expression profiles which are comprised of nine stem cell
types: Hematopoietic Stem Cells (HSC), Mesenchymal Stem Cells (MSC),
Embryonal Carcinoma (EC), Mammary Stem Cells (MaSC), Neural Stem Cells
(NSC), Intestinal Stem Cells (ISC), induced Pluripotent Stem Cells (iPSC) and
Spermatogonial Stem Cells (SSC).
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Purification of Total RNA
Total RNA was purified from individual CPC clones stored in RNA Protect
(Qiagen, Valencia, CA) and Qiazol Reagent (Qiagen, Valencia, CA). 1 ml of RNA
protect or 700 ul of Qiazol was used to lyse the cells before being centrifuged
though the provided RNeasy spin column followed by a series of washes with
provided buffers. RNA was eluted with RNAse-free water and optical density of
RNA was read using the Nanodrop 2000 to get the concentration of RNA. RNA
was run on a 1% agarose gel to assess purity (Park et al., 1996). First Strand
cDNA synthesis was performed from 2ug total RNA using Superscript III Reverse
Transcriptase (Invitrogen).
RT-PCR Analysis
RT-PCR was performed using the RT2 SYBR Green qPCR Master mix
and the plate was loaded into the iQ5 RT-PCR Cycler. PCR plates were run
under the following conditions: 94 °C for 10 min, 94 °C for 15 s, 58-60 °C
(depending on primer) for 1 min, 72 °C for 30 s, repeated for 45 cycles. Primers
for genes of interest are listed in table 2. RT-PCR products were visualized using
1%-2% agarose gel electrophoresis and a low mass DNA ladder was used to
assess the size of the PCR product. Fold changes were calculated using the
delta-delta Ct method (Schmittgen & Livak, 2008).
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Human
Forward Sequence
Reverse Sequence
Gene
SALL4 CACAAGTGTCGGAGCAGTCT
CCGTCCGTACCTAACAGAGC
SOX2
AACCAGCGCATGGACAGTTA
GACTTGACCACCGAACCCAT
EpCAM TGGGGAACAACTGGATCTGG
CCCACGCACACACATTTGTAA
TBX5
CTCAGTCCCCCGGAACAAC
CACGTACCTCCCAGCTCAAG
Tfap2c
TGGTTGGTTTTTGTGTCCGC
TTGCTTCGTGCCTACCCTTT
Actin TTTGAATGATGAGCCTTCGTCC GGTCTCAAGTCAGTGTACAGGTAA
CC
GC
Table 2: Gene specific primer pairs created with NCBI Primer-Blast were used in
the Reverse Transcription Polymerase Chain Reaction (Reported 5’ to 3’).

Statistics
Data was processed using Microsoft Excel and GraphPad Prism 7.02.
Transcriptomic data was used to generate heatmaps using GraphPad Prism
7.02.
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CHAPTER THREE
RESULTS

Transcriptomic Analysis Elucidates Age-Related Differences in StemnessExpression Profiles and Mechanistic Networks
Stem cells present a unique regenerative ability offering potential for
treatment of a variety of diseases. There are a number of stem cell types each
having a distinct gene expression profile. RNA-Seq based transcriptomics was
used to identify the expression profile and stemness features within the neonatal
and adult Isl-1+ CPC population. Using StemChecker, the Isl-1+ neonatal CPC
population (N=3) presented a gene expression profile most similar to induced
pluripotent stem cells (P-value=0.024). Specifically, of the nine expression
profiles curated by StemChecker, the transcriptome of the Isl-1+ neonatal CPC
population contained a higher percentage (forty-three percent) of transcripts
associated with iPSCs. In contrast, the transcriptome of the Isl-1+ adult CPC
population (N=3) presented a gene expression profile (forty-two percent) most
similar to mesenchymal stem cells (MSC) (P-value 2.01E-6) (Figure 2).
Transcripts associated with iPSCs and MSCs represent multipotentiality, selfrenewal ability, and proliferation. Both are promising cell sources for autologous
cell therapy and facilitate post-infarct recovery (Neef et al., 2022).
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Figure 2: StemChecker analysis comparing the iPSC and MSC expression profile
for Isl-1+ neonatal and adult CPCs. Isl-1+ neonatal CPC (N=3) transcriptome had
the greatest number of transcripts corresponding to iPSCs. Isl-1+ adult CPC
(N=3) transcriptome had the greatest number of transcripts corresponding to
MSCs.
Using RNA sequencing, gene expression profiles of the Isl-1+ neonatal
and adult CPC clonal populations were compared to one another. A fold change
cutoff of 2.0 was applied to focus on statistically significant gene expression
changes when comparing each age group. The neonatal population (N=3)
consisted of 2673 transcripts and the adult population (N=3) consisted of 1381
transcripts. Transcript sequence information was uploaded to Ingenuity Pathway
Analysis (IPA) software to identify transcripts implicated in mechanistic networks
(Figure 3). Mechanistic networks are signaling cascades that connect upstream
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regulators to visualize how they may work together to elicit gene expression
changes observed in experimental data (Kramer et al., 2014). A mechanistic
network was identified in the neonatal population data containing key stemness
genes: SOX2, OCT4, and Nanog. In addition, Gata 6, an early-stage
differentiation gene was found in the network (Fisher et al., 2017). This
mechanistic network was not identified in the adult population data. Stemness
gene, SALL4 was added to the network using Ingenuity Pathway Analysis grow
tool. IPA path explorer tool was used to determine the connection between
SALL4 and the stemness genes. The connections are based on the IPA
knowledge base which is curated from published experimental data. IPA’s
overlay tool allows analyses from different dataset uploads to be applied to a
network or pathway. The overlay tool was used to determine if the transcriptome
of the adult CPC population contains mRNAs implicated in the network. In
addition, IPA’s molecule activity predictor function was applied to the network to
identify predicted activation and inhibition of the molecules as determined by the
z-score. Figure 3 shows that the mechanistic network is predicted to be
activated in the neonatal population while the network shows no significant
activation or inhibition for the adult population. Within the network, genes
highlighted in red were identified within the transcriptomic dataset. The color of
the lines indicates the expected directional effect between two molecules based
on published literature.
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More Extreme
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Increased Measurement
More Extreme

Less

Predicted Activation
More Extreme

Less

Predicted Inhibition
Leads to activation
Leads to inhibition

Neonatal Islet-1+ CPC

Adult Islet-1+ CPC

Effect not predicted

Figure 3: Mechanistic network of upstream regulators and their predicted
regulators generated by IPA. Neonatal Isl-1+ CPCs (N=3) (left) show predicted
activation and/or inhibition of genes using IPA tool: molecule activity predictor.
Adult Isl-1+ CPCs (N=3) (right) shows insignificant prediction activation and/or
inhibition of genes using IPA tool: molecule activity predictor.
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Individual Islet-1 + Neonatal CPCs Exhibit Pathway Specific Transcriptomic
Differences
Using the comparative transcriptomic data of three individuals patientderived Isl-1+ neonatal CPC clones, all fold change values were entered into IPA
software to identify the differences and similarities within the neonatal population.
The cardiovascular stem cell clone expanded from an 8 day old patient (neonate
N1) showed enhanced expression of genes activated for calcium signaling,
transcriptional regulatory network in embryonic stem cells and factors promoting
cardiogenesis when compared with the clone that was isolated from neonate 3
(N3). Additionally, each Isl-1+ neonatal clone showed differences in pathwayspecific transcript expression levels when comparing neonate 1, neonate 2 and
neonate 3. SALL4 was found to be most highly expressed in the clone isolated
from the 8 day old patient. Although transcripts identified within the
Transcriptional Regulation of Pluripotent Stem Cell pathway were identified in
each of the three Isl-1+ neonatal CPC clones, neonate 1 expressed the highest
levels (Figure 4).
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N1

N2

N3

Figure 4: Heatmap of transcripts in the Transcriptional Regulation of Pluripotent
Stem Cells pathway in the three-patient derived Isl-1+ neonatal CPC clones (N1,
N2 and N3).
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Neonatal Islet-1+ CPCs Exhibit Stage Specific Transcriptomic Differences
Cardiogenesis begins at the start of gastrulation. Specifically, epiblast
cells ingress through the primitive streak to form the mesendoderm and
subsequently mesoderm. Stage specific gene expression during cardiogenesis is
used to identify differentiation steps in development. Comparing previously
published stage-specific RNA-seq transcriptomic data to our RNA-seq Isl-1+
neonatal CPC transcriptomic data yields stage specific differences in gene
expression within the Isl-1+ neonatal CPC clones (Figure 5). Stages of CPC
development are: Pluripotent/epiblast, pre-mesendoderm, mesendoderm, FHF
and SHF (Maher & Xu, 2013). Each individual Isl-1+ neonatal clone showed
differences in expression level. Specifically, the heatmap shows that N1
expresses the highest number of genes correlated to all CPC developmental
stages as opposed to N2 and N3.

N1 N2 N3
Figure 5: Heatmap of markers that identify stages (Pluripotent, premesendoderm, mesendoderm, FHF, SHF) of CPC development between the
individual neonatal Isl-1+ CPC clones.
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Transcriptomic Analysis Reveals a Correlation between SALL4, SOX2, EpCAM
and TBX5
IPA allows the search of individual genes to identify the predicted role of
SALL4 and shows interactions between genes based on experimental and
literature references. According to IPA, SALL4 interacts with SOX2, EpCAM and
TBX5 (Figure 6A). SALL4 increases the expression of SOX2 and vice versa by
interaction with their enhancer proteins (Yang et al., 2012). SALL4 and TBX5
also have a protein-protein interaction that impacts their expression (KoshibaTakeuchi et al., 2006). Activation of SALL4 is involved in upregulation of EpCAM
mRNA as shown in Figure 6A (Zeng et al., 2014). Neonate 1 shows the greatest
correlation of genes associated with SALL4 activation/function compared to
neonate 2 and 3 (Figure 6B).
B

A

N1 N2 N3
Figure 6: Genes and canonical pathways associated with SALL4 (A). Heatmap of
genes associated with SALL4 that are expressed in neonatal CPC clones N1, N2
and N3 (B).
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SALL4 is Expressed in Individual Islet-1+ Neonatal Cardiac Progenitor Cell
Clones
Clonal populations of human neonatal CPCs expressing Isl-1+ were
previously isolated and characterized for further use in the laboratory (Fuentes et
al., 2013). Additionally, the CPCs have previously been selected for expression
of early developmental markers such as Mesp1, PDGFRa, and SSEA1 (Baio et
al., 2018). SALL4 expression in Isl-1+ neonatal CPCs was therefore analyzed by
RT-PCR to confirm RNA-Seq analysis in the three sequenced clones and to
determine whether additional neonatal CPC clones express SALL4. Ten Isl-1+
neonatal CPC clones were screened for expression of SALL4 mRNA. Figure 7A
shows that SALL4 is expressed in 9 of the 10 Isl-1+ neonatal CPC clones,
confirming the RNA-seq data and identifying one neonatal CPC clone that did not
express SALL4. Figure 7B shows the corresponding actin expression for each
clone.
B

A

383
130

Figure 7: Gel Image of SALL4 (383 bp) expression in 10 Isl-1+ neonatal CPCs
(A) and corresponding actin (130 bp) (B) as detected by RT-PCR.
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SALL4 is Co-Expressed with SOX2, EpCAM and TBX5 in Neonate 1
We next used gene specific primers to assess expression of SOX2,
EpCAM and TBX5 via RT-PCR. Neonate 1 expresses SOX2, EpCAM, and TBX5
by RNA-Seq based transcriptomics (Figure 8). To confirm transcriptomic data,
neonate 1 was tested for expression of SOX2, EpCAM, and TBX5 by RT-PCR.
Figure 9 confirms the expression of these transcripts in neonate 1.

N1 N2 N3
Figure 8: Heatmap visualization generated from Isl-1+ neonatal RNA-Seq data
showing differentially expressed genes in neonate 1, neonate 2 and neonate 3
CPC clones. Red indicates a high gene expression level while green indicates a
low gene expression level.
Neonate 1
MW

TBX5

SALL4

400

(383)

EpCAM (466)

SOX2
(309)

(278)

Figure 9: Gel image of RT-PCR products: SALL4, SOX2, EpCAM and TBX5
mRNAs are expressed in neonate 1 as detected by RT-PCR.
28

SALL4 Expressing Islet-1+ CPCs are Sub-Staged by TFAP2C

A gene specific primer for transcription factor TFAP2C was used to further
define the developmental stage of the SALL4, SOX2, TBX5, and EpCAM
expressing Isl-1+ CPCs. The gene expression profile of Neonate 1, obtained
from the 8 day old patient, was consistent with that of an early mesendodermal
stage cell. Therefore, we sought to determine whether or not all day 8 CPC
clones have a gene expression profile similar to neonate 1. We compared three
independent CPC clones identified from different 8 day old neonates and found
that they all expressed transcripts encoding SALL4, SOX2, TBX5, and EpCAM .
According to Churko et al., TFAP2C is expressed on day 2 of directed
cardiomyocyte differentiation, with day 2 corresponding to early mesoderm.
Additionally, TFAP2C has been shown to drive mesendoderm competence and
shift the developmental trajectory toward the pluripotent state (Pastor et al.,
2018). We therefore performed a PCR experiment designed to determine
whether or not TFAP2C was expressed in any or all of these day 8 CPC clones.
Figure 10 shows that neonate 1(A) expresses TFAP2C while neonate 1(B) and
neonate 1(C) clonal samples do not, thereby confirming that the day 8 Isl-1+
neonatal CPCs are not all similar and can be sub-staged. Figure 11 shows a
heatmap derived from RT-PCR confirming the gel image in figure 10.
Additionally, TFAP2C expression confirms that neonate 1(A) represents the
earliest cardiac progenitor cell that can be isolated from neonatal human patient
samples.
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372

Figure 10: Gel image of TFAP2C (372 bp) mRNA expression in three 8-day old
Isl-1+ neonatal CPC clones which were derived from different patients
represented as neonate 1 (A), N (B) and N (C) and corresponding Actin (130 bp)
expression as detected by RT-PCR. TFAP2C was detected in neonate 1 (A).

Figure 11: Heatmap visualization of RT-PCR analysis of TFAP2C mRNA levels in
the 8-day old neonatal CPC clones represented as neonate 1 (A), N (B) and N
(C). RT-PCR was performed on cDNA using gene specific primers. Relative
quantification of each gene expression level was normalized according to actin
gene expression. Red indicates a high gene expression level while green
indicates a low gene expression level.
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CHAPTER FOUR
DISCUSSION

In the present study, clonal populations of Isl-1+ neonatal CPCs isolated
from the human heart were utilized to identify an early-stage CPC subpopulation.
The results show that SALL4 identifies a subpopulation at the premesendodermal stage of development. The identification of pre-mesendodermal
cells in neonatal Isl-1+ cardiovascular tissue using transcriptomics further
validates the neonate as a source of cells with enhanced stemness.
Mesendodermal stage cells can differentiate toward both mesoderm and
endoderm, rendering them precursors for numerous stem cell- based
applications. The new information reported here identifies markers that allow the
substaging of pre-mesendoderm/mesendoderm population of cardiovascular
progenitors in cardiovascular tissue derived from human patient samples. This
study identifies the earliest pre-mesendodermal cells that reside in, and can be
isolated from, the neonatal heart.
Currently there is limited evidence identifying the functional effect stage
specific cardiac progenitor cells on regeneration and/or the superiority of one
cell type over the other. Previous studies demonstrate the effectiveness of
using early-stage cells. For example, Blin et al., utilized SSEA-1+/Isl-1+ CPCs
derived from Rhesus ESCs in an allograft model of myocardial infarction. This
preclinical study revealed that upon transplantation of SSEA-1+/Isl-1+
progenitors scar tissue size was reduced, cells differentiated to ventricular
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myocytes and no teratoma was formed (Blin et al., 2010). These cells are
characterized as very early CPCs, segregating into the FHF and SHF. This
population is derived from Rhesus ESCs and goes through the mesendodermal
stage of development giving rise to the 3 main cardiac lineages of the heart
under induced cardiac differentiation. The absence of inappropriate
differentiation in vivo suggests that early-stage cells take cues from the cardiac
environment to achieve lineage specific differentiation.
Lineage tracing studies in mice showed that development of the heart and
hindlimb is regulated by Isl-1. Therefore, Isl-1+ may mark a subset of early-stage
progenitors that differentiate along a common heart/hindlimb pathway of
development (Yang et al., 2006). According to Akiyama et al., SALL4 plays a
critical role at early steps of limb development (Akiyama et al., 2015).
Specifically, inactivation of SALL4 in the mesendoderm before limb outgrowth
causes defects of proximal-anterior skeletal elements specifically in the hindlimbs
(Akiyama et al., 2015). While Isl-1+ has been elucidated in cardiac and hindlimb
progenitor cells, SALL4 has yet to be examined in CPCs.
The mesendoderm stage has been established in models such as mouse
and hPSCs. However, a homogenous niche of progenitors can segregate by
various mechanisms to form subpopulations with different fates. Transcriptomics
can give insight into the way we study cellular heterogeneity in vivo.
Characterization of different cell populations forming an embryo allows one to
make predictions about their ontogeny and showcase sets of genes that interact
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with each other to control specific cell functions (Sendra et al., 2021). This is
referred to as a gene regulatory network (GRN). An RNA-Seq analysis found that
in mESCs, the MesEndoderm Transcriptional Enhancer Organizing Region
(meteor) enhancer was found to be indispensable and hardwired in pluripotency
and a key determinant of lineage specification during development (Alexanian et
al., 2017). Alexaninan et al., sorted mesendodermal progenitors from
differentiating ESCs according to Eomes expression and found that enhancer
usage is coordinated with mesendoderm-specific expression of key lineage
determining factors. Induction of the meteor transcription at a pluripotent stage is
sufficient to promote mesendoderm specification and stimulate cardiogenic
differentiation. Stavish et al., found that the exit from pluripotency involves
intermediates that retain pluripotency while simultaneously exhibiting lineagebias (Stavish et al., 2020). They found that a substate of human PSCs expressed
the early endoderm marker GATA 6. GATA 6 positive cells were able to
regenerate long-term pluripotent cultures and differentiate toward the
endodermal lineage. This explains that substates that co-express pluripotency
and differentiation markers represent differentiation intermediates, and these
may exist as transient states during development. A study by Mononen et al.,
used trajectory mapping and RNA seq analysis to reveal branch points in hESC
cardiac differentiation which resulted in a continuous pluripotent to cardiomyocyte
differentiation trajectory (Mononen et al., 2020). This trajectory revealed that
multiple lineages branch off of the pluripotent cluster of cells such as: cardiac
mesoderm, endoderm-like cells, and fibroblast like cells. Interestingly, a global
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transcriptional dynamics analysis across time showed that gene expression
differed significantly between days 3 and 6 suggesting that up until day 6, cells
rapidly progress through transient and distinct cellular states until day 7
(Mononen et al., 2020). Upon analysis of Mononen et al., published
transcriptomic data: the pluripotent cluster, cardiac mesoderm cluster, and
endoderm cluster all expressed SALL4. Taken together, these studies support
the concept that the expression of markers of mesendoderm as well as
pluripotency represents an intermediate cell stage that is very early along that
cardiovascular path.
Using transcriptomic analysis, we found that select Isl-1+ neonatal CPCs
expressed cardiac lineage and pluripotency markers. Additionally,
transcriptomics revealed that human neonatal Isl-1+ CPCs have a gene
expression profile similar to iPSCs. Alternatively, adult Isl-1+ CPCs expressed a
gene profile similar to that of MSCs. The adult Isl-1+ CPCs did not express
stemness genes indicating that neonates have enhanced stemness properties.
This demonstrates that neonatal Isl-1+ CPCs derived from human heart tissue
are at a very early stage along the path to becoming cardiovascular cells.
Transcriptomic analysis showed that Isl-1+ neonatal CPC clones have genes
involved in the transcriptional regulation of pluripotency pathway which includes
transcription factor SALL4 (Figure 4). This pathway activates expression of other
pluripotency associated factors while repressing lineage specific genes and
activating their own gene expression (Yeo & Ng, 2013). This model accounts for
how cells can sustain self-renewal and pluripotency while remaining poised for
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differentiation. While SALL4 was found to be prevalent in the Isl-1+ CPC clones
tested, transcriptomic analysis of Isl-1+ neonatal CPCs using IPA revealed that
SALL4 interacts with TBX5, EpCAM and SOX2.
SALL4 co-expressing Isl-1+ neonatal CPCs expressed transcripts which
are involved early in embryonic development such as TBX5, SOX2, and EpCAM.
A subpopulation co-expressing these genes suggests that this subpopulation
may reside in a stage of development earlier than the mesendoderm. Using a
microarray analysis, Tanimura et al., found that SALL4 and SOX2 bind to the
promoter region of the same genes in ESCs. This suggests that the SALL4 and
SOX2 overlapping gene set is enriched for genes involved in maintaining
pluripotency (Tanimura et al., 2013). Next, SALL4 plays a role in various tissues
and organs during embryonic development. Disruption of SALL4 in ESCs results
in early embryo defects and lethality during peri-implantation (Yang et al., 2018).
Additionally, heterozygous disruption of the SALL4 allele leads to multi-organ
malformations including limb and heart defects (Pantier et al., 2021). Specifically,
TBX5 regulates SALL4 expression in the developing heart and forelimb and
interacts with SALL4 to synergistically regulate downstream gene expression.
According to Abboud et al., mesodermal and cardiac gene expression in OCT4induced human mesendodermal, mesodermal and neighboring cells was
monitored by lineage tracing analysis in the presence or absence of SALL4
(Abboud et al., 2015). Results showed that expression of genes that play a role
in cardiac development such as, MESP1, MYOCD, GATA4, TBX5, Isl-1 and
Mef2c were induced to a lesser extent in the absence of SALL4. This suggests
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that SALL4/TBX5/ SOX2/EpCAM co-expressing Isl-1+ cardiac progenitors reside
early in embryonic development. Given that SALL4, SOX2, EpCAM, and TBX5
expression was found to be prevalent in the Isl-1+ neonatal CPC clones,
TFAP2C was identified to further sub-stage these cells. Transcriptomics data
published by Churko et al., demonstrated that TFAP2C is expressed transiently
at day 2 of directed cardiomyocyte differentiation from hiPSCs. Additionally,
Valcourt et al., revealed that overexpression of TFAP2C hindered movement
along the hESC developmental trajectory, shifting cells toward the pluripotent
state while remaining poised for mesendoderm specification (Valcourt et al.,
2021).
The present study sought to identify a subpopulation of Isl-1+ neonatal
CPCs. Our findings demonstrate that SALL4 is co-expressed in select Isl-1+ CPC
clones. This pre-mesendodermal CPC is associated with the early stages of
embryonic development and preserves characteristics of an intermediate cell
state between pluripotency and mesendoderm. Overall, SALL4 functions to
maintain stemness, plays a role in cell expansion and early embryonic and
cardiac development. Risks of stem cell transplantation includes immune
rejection and teratoma. A study by Cao et al., utilized multilineage differentiating
stress enduring cells (MUSE Cells) for MI (Cao et al., 2020). These cells express
pluripotency and linage biased markers and do not reject after transplantation.
The MUSE cells express HLA-G which has been shown to promote graft
tolerance in heart transplantation which protects MUSE cells from immunologic
attack (Young, 2018). Furthermore, while iPSCs have been proven to be
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beneficial for cardiac repair, they possess some degree of variation between cell
lines and typically match the genomic profile of the donor. Studies have shown
that stem cell derived cardiomyocytes have immature calcium handling (Satin et
al., 2008) and lack maturity or metabolic characteristics of mature CM found in
the healthy heart (Veerman et al., 2015). However, a study by Maxwell et al.,
revealed that application of mechanical and electrical stimuli to early-stage cells
can induce morphological and functional maturation of hiPSC-CMs to adult like
human cardiac tissue. Early-stage intensity trained cardiac tissue increased
expression of genes associated with adult-like conduction, maturation,
energetics, and calcium handling. Maxwell et al., shows that intensity training
may allow for the achievement of a more advanced level of maturation in vivo
(Maxwell & Xu, 2018). Another feature of early-stage cells is their cellular
plasticity which has been reported in vivo after primitive heart tube formation
(Meilhac & Buckingham, 2018). This reveals that the differentiation of CPCs is
not fixed and can change upon positional cues or intrinsic signaling. To date, not
a single cell type has been approved by the FDA for treatment of any form of
heart disease. The results reported here provide new insight into the various
stages of neonatal Isl-1+ CPCs which can be isolated from human tissue. The
ability to isolate and expand these early-stage cells for experimental and clinical
applications may prove to be valuable as the search for an optimal cell source for
cardiac regenerative therapy continues.

37

REFERENCES
Abboud, N., Morris, T., Hiriart, E. et al. A cohesin–OCT4 complex mediates Sox
enhancers to prime an early embryonic lineage. Nat Commun 6, 6749
(2015). https://doi.org/10.1038/ncomms7749.
Akiyama, Ryutaro, et al. “Sall4-Gli3 System in Early Limb Progenitors Is Essential
for the Development of Limb Skeletal Elements.” Proceedings of the
National Academy of Sciences, vol. 112, no. 16, Apr. 2015, pp. 5075–80.
DOI.org (Crossref), https://doi.org/10.1073/pnas.1421949112.
Alexanian, Michael, et al. “A Transcribed Enhancer Dictates Mesendoderm
Specification in Pluripotency.” Nature Communications, vol. 8, no. 1, Dec.
2017, p. 1806. DOI.org (Crossref), https://doi.org/10.1038/s41467-01701804-w.
Andersen, Peter, et al. “Precardiac Organoids Form Two Heart Fields via
Bmp/Wnt Signaling.” Nature Communications, vol. 9, no. 1, Dec. 2018, p.
3140. DOI.org (Crossref), https://doi.org/10.1038/s41467-018-05604-8.
Baio, J., Martinez, A.F., Silva, I. et al. Cardiovascular progenitor cells cultured
aboard the International Space Station exhibit altered developmental and
functional

properties.

npj

Microgravity

4,

13

(2018).

https://doi.org/10.1038/s41526-018-0048-x.
Barreto, Sara, et al. “Cardiac Progenitor Cells from Stem Cells: Learning from
Genetics and Biomaterials.” Cells, vol. 8, no. 12, Nov. 2019, p. 1536.
DOI.org (Crossref), doi:10.3390/cells8121536.

38

Bartulos, Oscar, et al. “ISL1 Cardiovascular Progenitor Cells for Cardiac Repair
after Myocardial Infarction.” JCI Insight, vol. 1, no. 10, July 2016. DOI.org
(Crossref), doi:10.1172/jci.insight.80920.
Belair, David G., et al. “Thalidomide Inhibits Human IPSC Mesendoderm
Differentiation by Modulating CRBN-Dependent Degradation of SALL4.”
Scientific Reports, vol. 10, no. 1, Dec. 2020, p. 2864. DOI.org (Crossref),
https://doi.org/10.1038/s41598-020-59542-x.
Blin, Guillaume et al. “A purified population of multipotent cardiovascular
progenitors derived from primate pluripotent stem cells engrafts in
postmyocardial infarcted nonhuman primates.” The Journal of clinical
investigation vol. 120,4 (2010): 1125-39. doi:10.1172/JCI40120.
Boumelhem BB, Assinder SJ, Hammans C, Tanudiastro MP, Le DTM, Brigden
KWL, Fraser ST (2017) The mesendoderm: a wellspring of cell lineages
for regenerative medicine. In: Frontiers in stem cell and regenerative
medicine research, vol 4. Bentham Science Publishers, Sharjah, pp 3–6
Cai, Chen-Leng, et al. “Isl1 Identifies a Cardiac Progenitor Population That
Proliferates Prior to Differentiation and Contributes a Majority of Cells to
the Heart.” Developmental Cell, vol. 5, no. 6, Dec. 2003, pp. 877–
89. DOI.org (Crossref), https://doi.org/10.1016/S1534-5807(03)00363-0.
Camberos, Victor, et al. “The Impact of Spaceflight and Microgravity on the
Human

Islet-1+

Cardiovascular

Progenitor

Cell

Transcriptome.”

International Journal of Molecular Sciences, vol. 22, no. 7, Mar. 2021, p.
3577. DOI.org (Crossref), doi:10.3390/ijms22073577.
39

Cao, Jiankun, et al. “Regenerative Potential of Pluripotent Nontumorgenetic Stem
Cells: Multilineage Differentiating Stress Enduring Cells (Muse Cells).”
Regenerative Therapy, vol. 15, Dec. 2020, pp. 92–96. DOI.org (Crossref),
https://doi.org/10.1016/j.reth.2020.04.011.
Carpenedo, Richard L et al. “Transcriptomically Guided Mesendoderm Induction
of Human Pluripotent Stem Cells Using a Systematically Defined Culture
Scheme.” Stem

cell

reports vol.

13,6

(2019):

1111-1125.

doi:10.1016/j.stemcr.2019.11.001
Churko, Jared M., et al. “Defining Human Cardiac Transcription Factor
Hierarchies Using Integrated Single-Cell Heterogeneity Analysis.” Nature
Communications, vol. 9, no. 1, Dec. 2018, p. 4906. DOI.org (Crossref),
https://doi.org/10.1038/s41467-018-07333-4.
den Hartogh, Sabine C., et al. “A Comprehensive Gene Expression Analysis at
Sequential Stages of in Vitro Cardiac Differentiation from Isolated MESP1Expressing-Mesoderm Progenitors.” Scientific Reports, vol. 6, no. 1, May
2016, p. 19386. DOI.org (Crossref), https://doi.org/10.1038/srep19386.
Drakhlis, Lika, et al. “Human Heart-Forming Organoids Recapitulate Early Heart
and Foregut Development.” Nature Biotechnology, vol. 39, no. 6, June
2021, pp. 737–46. DOI.org (Crossref), https://doi.org/10.1038/s41587021-00815-9.
“EjectionFraction.” ClevelandClinic,
https://my.clevelandclinic.org/health/articles/16950-ejection-fraction.
Accessed 15 Mar. 2022.
40

Fisher, J. B., et al. “GATA6 Is Essential for Endoderm Formation from Human
Pluripotent Stem Cells.” Biology Open, Jan. 2017, p. bio.026120. DOI.org
(Crossref), https://doi.org/10.1242/bio.026120.
Foo, Kylie S., et al. “Human ISL1+ Ventricular Progenitors Self-Assemble into an
In Vivo Functional Heart Patch and Preserve Cardiac Function Post
Infarction.” Molecular Therapy, vol. 26, no. 7, July 2018, pp. 1644–59.
DOI.org (Crossref), doi:10.1016/j.ymthe.2018.02.012.
Fuentes, Tania I., et al. “Human Neonatal Cardiovascular Progenitors:
Unlocking the Secret to Regenerative Ability.” PLoS ONE, edited by
Maurizio Pesce, vol. 8, no. 10, Oct. 2013, p. e77464. DOI.org (Crossref),
doi:10.1371/journal.pone.0077464.
Fuerstenau-Sharp, Maya, et al. “Generation of Highly Purified Human
Cardiomyocytes from Peripheral Blood Mononuclear Cell-Derived Induced
Pluripotent Stem Cells.” PLOS ONE, edited by Katriina Aalto-Setala, vol.
10,

no.

5,

May

2015,

p.

e0126596. DOI.org

(Crossref),

https://doi.org/10.1371/journal.pone.0126596.
Gao, Rui, et al. “Pioneering Function of Isl1 in the Epigenetic Control of
Cardiomyocyte Cell Fate.” Cell Research, vol. 29, no. 6, June 2019, pp.
486–501. DOI.org (Crossref), doi:10.1038/s41422-019-0168-1.
“HeartSurgery.”Asahq.Org,2021,https://www.asahq.org/madeforthismoment/pre
paring-for-surgery/procedures/heart-surgery/.
Jia, Guangshuai, et al. “Single Cell RNA-Seq and ATAC-Seq Analysis of
Cardiac Progenitor Cell Transition States and Lineage
41

Settlement.” Nature Communications, vol. 9, no. 1, Dec. 2018, p.
4877. DOI.org (Crossref), https://doi.org/10.1038/s41467-018-07307-6.
Koshiba-Takeuchi, Kazuko, et al. “Cooperative and Antagonistic Interactions
between Sall4 and Tbx5 Pattern the Mouse Limb and Heart.” Nature
Genetics, vol. 38, no. 2, Feb. 2006, pp. 175–83. DOI.org (Crossref),
doi:10.1038/ng1707.
Krämer, Andreas et al. “Causal analysis approaches in Ingenuity Pathway
Analysis.” Bioinformatics (Oxford, England) vol. 30,4 (2014): 523-30.
doi:10.1093/bioinformatics/btt703
Le, Tyl, and Jjh Chong. “Cardiac Progenitor Cells for Heart Repair.” Cell Death
Discovery, vol. 2, no. 1, Dec. 2016, p. 16052. DOI.org (Crossref),
doi:10.1038/cddiscovery.2016.52.
Ma, Q., Zhou, B., and Pu, W. T. (2008). Reassessment of Isl1 and Nkx2-5
Cardiac

Fate

Maps

Using

a

Gata4-Based

Reporter

of

Cre

Activity. Develop. Biol. 323, 98–104. doi:10.1016/j.ydbio.2008.08.013
Maher, Kevin O, and Chunhui Xu. “Marching towards regenerative cardiac
therapy with human pluripotent stem cells.” Discovery medicine vol. 15,85
(2013): 349-56.
Maxwell, Joshua T., and Chunhui Xu. “Stem-Cell-Derived Cardiomyocytes Grow
Up: Start Young and Train Harder.” Cell Stem Cell, vol. 22, no. 6, June
2018,

pp.

790–91.

https://doi.org/10.1016/j.stem.2018.05.011.

42

DOI.org

(Crossref),

Meilhac SM, Buckingham ME. The deployment of cell lineages that form the
mammalian heart. Nat Rev Cardiol. 2018 Nov;15(11):705-724. doi:
10.1038/s41569-018-0086-9. PMID: 30266935.
Meilhac, Sigolène M., et al. “The Clonal Origin of Myocardial Cells in Different
Regions of the Embryonic Mouse Heart.” Developmental Cell, vol. 6, no.
5, May 2004, pp. 685–98. DOI.org (Crossref),
https://doi.org/10.1016/S1534-5807(04)00133-9.
Menasché, Philippe, et al. “Human Embryonic Stem Cell-Derived Cardiac
Progenitors for Severe Heart Failure Treatment: First Clinical Case Report:
Figure 1.” European Heart Journal, vol. 36, no. 30, Aug. 2015, pp. 2011–
17. DOI.org (Crossref), doi:10.1093/eurheartj/ehv189.
Menasché, Philippe. “Cell Therapy With Human ESC-Derived Cardiac Cells:
Clinical Perspectives.” Frontiers in Bioengineering and Biotechnology, vol.
8,

Oct.

2020,

p.

601560.

DOI.org

(Crossref),

https://doi.org/10.3389/fbioe.2020.601560.
Miller, Anzy, et al. “Sall4

Controls Differentiation of Pluripotent Cells

Independently of the Nucleosome Remodelling and Deacetylation (NuRD)
Complex.” Development, Jan. 2016, p. dev.139113. DOI.org (Crossref),
doi:10.1242/dev.139113.
Mononen, Mimmi M., et al. “Trajectory Mapping of Human Embryonic Stem Cell
Cardiogenesis Reveals Lineage Branch Points and an ISL1 ProgenitorDerived Cardiac Fibroblast Lineage.” Stem Cells, vol. 38, no. 10, Oct.
2020,pp. 1267–78. DOI.org (Crossref), https://doi.org/10.1002/stem.3236.
43

Mozaffarian, Dariush, et al. “Heart Disease and Stroke Statistics—2015 Update:
A Report From the American Heart Association.” Circulation, vol. 131,
no. 4, Jan. 2015. DOI.org (Crossref),
doi:10.1161/CIR.0000000000000152.
Muhr J, Ackerman KM. Embryology, Gastrulation. 2021 Apr 15. In: StatPearls
[Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID:
32119281.
Neef, Klaus, et al. “Co-Transplantation of Mesenchymal Stromal Cells and
Induced Pluripotent Stem Cell-Derived Cardiomyocytes Improves Cardiac
Function After Myocardial Damage.” Frontiers in Cardiovascular Medicine,
vol.

8,

Jan.

2022,

p.

794690.

DOI.org

(Crossref),

https://doi.org/10.3389/fcvm.2021.794690.
Pantier, Raphaël, et al. “SALL4 Controls Cell Fate in Response to DNA Base
Composition.” Molecular Cell, vol. 81, no. 4, Feb. 2021, pp. 845-858.e8.
DOI.org (Crossref), doi:10.1016/j.molcel.2020.11.046.
Pantier, Raphaël, et al. “SALL4 Controls Cell Fate in Response to DNA Base
Composition.” Molecular Cell, vol. 81, no. 4, Feb. 2021, pp. 845-858.e8.
DOI.org (Crossref), https://doi.org/10.1016/j.molcel.2020.11.046
Park, EJ, et al. A Simplified Electrophoresis Method for Analyses of High
Molecular Weight RNA . no. 1, 1996, pp. 23–26.
Pastor, W.A., Liu, W., Chen, D. et al. TFAP2C regulates transcription in human
naive pluripotency by opening enhancers. Nat Cell Biol 20, 553–564 (2018).
https://doi.org/10.1038/s41556-018-0089-0.
44

Pawani, Harsha, and Deepa Bhartiya. “Pluripotent stem cells for cardiac
regeneration: overview of recent advances & emerging trends.” The Indian
journal of medical research vol. 137,2 (2013): 270-82.
Peterson, Joshua C., et al. “The Role of Cell Tracing and Fate Mapping
Experiments in Cardiac Outflow Tract Development, New Opportunities
through Emerging Technologies.” Journal of Cardiovascular
Development and Disease, vol. 8, no. 5, Apr. 2021, p. 47. DOI.org
(Crossref), https://doi.org/10.3390/jcdd8050047.
Pinto, José P., et al. “StemChecker: A Web-Based Tool to Discover and Explore
Stemness Signatures in Gene Sets.” Nucleic Acids Research, vol. 43, no.
W1,

July

2015,

pp.

W72–77.

DOI.org

(Crossref),

https://doi.org/10.1093/nar/gkv529.Rna gel ref
Ren, Jie, et al. “Spotlight on Isl1: A Key Player in Cardiovascular Development
and Diseases.” Frontiers in Cell and Developmental Biology, vol. 9, Nov.
2021,

p.

793605.

DOI.org

(Crossref),

https://doi.org/10.3389/fcell.2021.793605.
Reuther, Jacquelyn, et al. “Transcriptome Sequencing (RNA-Seq).” Genomic
Applications in Pathology, edited by George Jabboure Netto and Karen L.
Kaul, Springer International Publishing, 2019, pp. 33–49. DOI.org
(Crossref), doi:10.1007/978-3-319- 96830-8_4.
Satin, Jonathan, et al. “Calcium Handling in Human Embryonic Stem Cell-Derived
Cardiomyocytes.” Stem Cells, vol. 26, no. 8, Aug. 2008, pp. 1961–72.
DOI.org (Crossref), https://doi.org/10.1634/stemcells.2007-0591.
45

Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the
comparative CT method. Nature protocols 3: 1101–1108.
Search of: Autologous Cardiac Progenitor Cells | Heart Disease, Ischemic - List
ResultsClinicalTrials.Gov.https://clinicaltrials.gov/ct2/results?cond=Heart
+Disease%2C+Ischemic&term=autologous+cardiac+progenitor+cells&cn
try=&state=&city=&dist=&Search=Search. Accessed 24 June 2021.
Sendra, Miquel, et al. “Dissecting the Complexity of Early Heart Progenitor Cells.”
Journal of Cardiovascular Development and Disease, vol. 9, no. 1, Dec.
2021, p. 5. DOI.org (Crossref), https://doi.org/10.3390/jcdd9010005.
Stavish, Dylan, et al. “Generation and Trapping of a Mesoderm Biased State of
Human Pluripotency.” Nature Communications, vol. 11, no. 1, Dec. 2020,
p. 4989. DOI.org (Crossref), https://doi.org/10.1038/s41467-020-18727-8.
Tahara, Naoyuki, et al. “Sall4 Regulates Neuromesodermal Progenitors and
Their Descendants during Body Elongation in Mouse Embryos.”
Development,

Jan.

2019,

p.

dev.177659.

DOI.org

(Crossref),

doi:10.1242/dev.177659.
Tan, Cheryl Mei Jun, and Adam James Lewandowski. “The Transitional Heart:
From Early Embryonic and Fetal Development to Neonatal Life.” Fetal
Diagnosis and Therapy, vol. 47, no. Suppl. 5, 2020, pp. 373–86. DOI.org
(Crossref), https://doi.org/10.1159/000501906.
Tanimura, Nobuyuki et al. “Stemness-related factor Sall4 interacts with
transcription factors Oct-3/4 and Sox2 and occupies Oct-Sox elements in
mouse embryonic stem cells.” The Journal of biological chemistry vol.
46

288,7 (2013): 5027-38. doi:10.1074/jbc.M112.411173
Tatetsu, Hiro, et al. “SALL4, the Missing Link between Stem Cells, Development
and Cancer.” Gene, vol. 584, no. 2, June 2016, pp. 111–19. DOI.org
(Crossref), doi:10.1016/j.gene.2016.02.019.
Tian TV, Di Stefano B, Stik G, Vila-Casadesús M, Sardina JL, Vidal E, Dasti A,
Segura-Morales C, De Andrés-Aguayo L, Gómez A, Goldmann J,
Jaenisch R, Graf T. Whsc1 links pluripotency exit with mesendoderm
specification. Nat Cell Biol. 2019 Jul;21(7):824-834. doi: 10.1038/s41556019-0342-1. Epub 2019 Jun 24. PMID: 31235934; PMCID: PMC8020485
Vahdat, Sadaf, et al. “Expansion of Human Pluripotent Stem Cell-Derived Early
Cardiovascular

Progenitor

Cells

by

a

Cocktail

of

Signaling

Factors.” Scientific Reports, vol. 9, no. 1, Dec. 2019, p. 16006. DOI.org
(Crossref), https://doi.org/10.1038/s41598-019-52516-8.
Valcourt, James R et al. “Modulating mesendoderm competence during human
germ layer differentiation.” Cell reports vol. 37,6 (2021): 109990.
doi:10.1016/j.celrep.2021.109990
Veerman, Christiaan C., et al. “Immaturity of Human Stem-Cell-Derived
Cardiomyocytes in Culture: Fatal Flaw or Soluble Problem?” Stem Cells
and Development, vol. 24, no. 9, May 2015, pp. 1035–52. DOI.org
(Crossref), https://doi.org/10.1089/scd.2014.0533.
Virani, Salim S., et al. “Heart Disease and Stroke Statistics—2021 Update: A
Report From the American Heart Association.” Circulation, vol. 143, no.
8, Feb. 2021. DOI.org (Crossref), doi:10.1161/CIR.0000000000000950.
47

Wang, Lingjun, et al. “Transplantation of Isl1+ Cardiac Progenitor Cells in Small
Intestinal Submucosa Improves Infarcted Heart Function.” Stem Cell
Research & Therapy, vol. 8, no. 1, Dec. 2017, p. 230. DOI.org (Crossref),
https://doi.org/10.1186/s13287-017-0675-2
Weinberger, Florian, et al. “Localization of Islet-1–Positive Cells in the Healthy
and Infarcted Adult Murine Heart.” Circulation Research, vol. 110, no. 10,
May

2012,

pp.

1303–10.

DOI.org

(Crossref),

doi:10.1161/CIRCRESAHA.111.259630.
Witman, Nevin, et al. “Cardiac Progenitors and Paracrine Mediators in
Cardiogenesis

and

Heart

Regeneration.”

Seminars

in

Cell

&

Developmental Biology, vol. 100, Apr. 2020, pp. 29–51. DOI.org
(Crossref), https://doi.org/10.1016/j.semcdb.2019.10.011.
Xiong J. SALL4: engine of cell stemness. Curr Gene Ther. 2014;14(5):400-11.
doi: 10.2174/1566523214666140825125138. PMID: 25174577.
Xiong, Haiqing, and Aibin He. “Single-Cell Transcriptomic Analysis of Cardiac
Progenitor Differentiation.” Current Cardiology Reports, vol. 22, no. 6,
June 2020, p. 38. DOI.org (Crossref), doi:10.1007/s11886-020-01285-2.
Yang, Feikun, et al. “Sumoylation Is Important for Stability, Subcellular
Localization, and Transcriptional Activity of SALL4, an Essential Stem Cell
Transcription Factor.” Journal of Biological Chemistry, vol. 287, no. 46,
Nov.

2012,

pp.

38600–08.

doi:10.1074/jbc.M112.391441.

48

DOI.org

(Crossref),

Yang, Jianchang. “SALL4 as a transcriptional and epigenetic regulator in normal
and leukemic hematopoiesis.” Biomarker research vol. 6 1. 3 Jan. 2018,
doi:10.1186/s40364-017-0115-6
Yang, L., Cai, C.-L., Lin, L., Qyang, Y., Chung, C., Monteiro, R. M., et al. (2006).
Isl1Cre Reveals a Common Bmp Pathway in Heart and Limb
Development. Development 133, 1575–1585. doi:10.1242/dev.02322
Yeo, Jia-Chi, and Huck-Hui Ng. “The Transcriptional Regulation of Pluripotency.”
Cell Research, vol. 23, no. 1, Jan. 2013, pp. 20–32. DOI.org (Crossref),
https://doi.org/10.1038/cr.2012.172.
Young W. Future of Muse Cells. Adv Exp Med Biol. 2018;1103:309-315. doi:
10.1007/978-4-431-56847-6_18. PMID: 30484238.
Zeng SS, Yamashita T, Kondo M, Nio K, Hayashi T, Hara Y, Nomura Y, Yoshida
M, Hayashi T, Oishi N, Ikeda H, Honda M, Kaneko S. The transcription
factor SALL4 regulates stemness of EpCAM-positive hepatocellular
carcinoma.

J

Hepatol.

2014

Jan;60(1):127-34.

10.1016/j.jhep.2013.08.024. Epub 2013 Sep 6. PMID: 24012616.

49

doi:

50

51

